



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3569515>Available online at: <http://www.iajps.com>

Research Article

**ANALYSIS OF RISK FACTORS AND MANAGEMENT OF
PREECLAMPSIA AND ECLAMPSIA IN PATIENTS**Dr Maryyam Rana¹, Dr Madiha Yousaf², Dr Natalia Narmeen³¹Woman Medical Officer Jinnah Hospital Lahore²Fatima Jinnah Medical University³BHU Ahmad Naich**Abstract:**

The basic aim of the study is to analyze the risk factors and management of preeclampsia and eclampsia patients. This cross sectional study was conducted at Jinnah Hospital, Lahore during March 2019 to September 2019. For this purpose we collected the data from 100 female participants. We collected the demographic data as well as family history of participants. Data was gathered using a pre-tested questionnaire. The questionnaire was administered to both cases and controls by the first author. We collected the data from 100 participants. In this study, the mean age of cases and controls were 24.4 ± 4.2 years and 23.9 ± 3.6 years respectively. In bivariate analysis nulliparity, primigravida, twin pregnancy, bad obstetrics history and history of abortion were not significantly associated with development of PE. It is concluded that those who have been diagnosed with severe preeclampsia are more likely to experience recurrence in their next pregnancy; however, the phenotype is typically less severe, with presentation approximately 2–3 weeks later in gestation.

Corresponding author:**Dr. Maryyam Rana,**

Woman Medical Officer Jinnah Hospital Lahore

QR code



Please cite this article in press Maryyam Rana et al., *Analysis Of Risk Factors And Management Of Preeclampsia And Eclampsia In Patients.*, Indo Am. J. P. Sci, 2019; 06(12).

INTRODUCTION:

Preeclampsia and eclampsia (PE) are major pregnancy specific syndromes that contribute to maternal and fetal morbidity and mortality in India. The incidence of PE ranges from 2% to 10%, depending on the population studied and criteria used for diagnosis. PE are gestational hypertensive disorders develop after 22 weeks of pregnancy, in which there is an increase in blood pressure and proteinuria. Preeclampsia causes abortion, prematurity, intra-uterine growth retardation and still birth¹. It is believed to be of multifactorial origin. Pre-eclampsia (PE) is a major cause of maternal and fetal mortality and morbidity. In general, the incidence of PE ranges between 2 and 10% worldwide. In an average UK population, the incidence of PE is less than 1 in 20 women. According to the National Institute of Clinical Excellence (NICE) antenatal guidelines, a woman's level of risk for PE in a given pregnancy should be assessed at the first antenatal visit by identifying the presence of one or more predisposing historical risk factors, and they should be supervised more vigilantly and managed at centers with facilities for specialized neonatal and maternal intensive care².

Preeclampsia and eclampsia (PE) are major pregnancy specific syndromes that contribute to maternal and fetal morbidity and mortality in India. The incidence of PE ranges from 2% to 10%, depending on the population studied and criteria used for diagnosis³⁻⁴. PE are gestational hypertensive disorders develop after 22 weeks of pregnancy, in which there is an increase in blood pressure and proteinuria. Preeclampsia causes abortion, prematurity, intra-uterine growth retardation and still birth. It is believed to be of multifactorial origin⁵. Proper antenatal care remains the important part of prevention. Estimating each woman's individualized risk allow antenatal surveillance to be directed at those women, who are most likely to develop preeclampsia⁶.

Objectives of the study

The basic aim of the study is to analyze the risk factors and management of preeclampsia and eclampsia patients.

METHODOLOGY OF THE STUDY:

This cross sectional study was conducted at Jinnah Hospital, Lahore during March 2019 to September 2019. For this purpose we collected the data from 100 female participants. We collected the demographic data as well as family history of participants. Data was gathered using a pre-tested questionnaire. The questionnaire was administered to both cases and controls by the first author. The questionnaire included demographic and socio-economic information. The history of gravidity, parity, abortion, bad obstetrics history, past history of eclampsia, diabetes mellitus and hypertension were elicited. Both cases and controls were asked about their food intake patterns during pregnancy (cereals, pulses, egg, meat, fish, sugar, milk and dairy products and fruits) by using food frequency questionnaire.

Statistical analysis

Student's t-test was performed to evaluate the data. The relations of BP to other variables were analyzed by linear regression and Pearson correlation coefficients. Multiple regression analysis studied the interdependence of these relations among variables found to correlate significantly with BP. Data are expressed as the mean \pm SD.

RESULTS:

We collected the data from 100 participants. In this study, the mean age of cases and controls were 24.4 ± 4.2 years and 23.9 ± 3.6 years respectively. Socio-economic risk factors such as maternal age, paternal age, education level, family income, occupation, type of family were not significantly associated with development of PE. In bivariate analysis nulliparity, primigravida, twin pregnancy, bad obstetrics history and history of abortion were not significantly associated with development of PE (table 01).

Table 01: Bivariate analysis showing obstetric risk factors for PE

Obstetric factors	Case n (%)	Control n (%)	OR (95% CI)	P value
Parity				
0	73 (59.8)	76 (62.3)	0.90 (0.52-1.56)	0.375
≥1	49 (40.2)	46 (37.7)	1.00	
Gravidity				
1	56 (45.9)	66 (54.1)	0.72 (0.42-1.23)	0.162
≥2	66 (54.0)	56 (46.0)	1.00	
Number of infants				
Twins	8 (6.6)	2 (1.6)	4.21 (0.8-29.36)	0.05
Singleton	114 (93.4)	120 (98.4)	1.00	
Duration between present and previous pregnancy				
<1 years	8 (6.5)	14 (11.2)	0.56 (0.21-1.5)	0.21
1-5 years	107 (88.6)	105 (89.3)	1.00	
≥5 years	6 (4.9)	3 (2.5)	1.96 (0.42-10.20)	0.49
History of abortion before this pregnancy				
Yes	8 (6.5)	14 (11.2)	0.54 (0.2-1.45)	0.18
No	114 (93.5)	108 (88.8)	1.00	
Bad obstetrics history				
Yes	37 (30.3)	27 (22.1)	1.53 (0.83-2.84)	0.146
No	85 (69.7)	95 (77.9)	1.00	

†NA;Not applicable; PE:Preeclampsia and eclampsia; OR:Odds ratio; CI:Confidence interval

DISCUSSION

The risk factors identified that influence the development of preeclampsia included extremes of maternal age, race, socio-economic factors, change of paternity, twin pregnancy, nulliparity, increased birth interval, increased BMI, increased systolic and diastolic blood pressure early in pregnancy, increased rate of weight gain during pregnancy and the presence of gestational diabetes⁸.

The management of preeclampsia has not changed significantly over time, possibly as a result of the poor progress being made in our understanding of the condition. Effective management of preeclampsia may be divided into three categories; prevention of preeclampsia, early detection, and treatment⁹. Women considered to be at high risk of preeclampsia (such as those with chronic hypertension, coexisting renal disease, or antiphospholipid syndrome should be referred for pre-pregnancy counseling to identify modifiable risk factors). This management may involve cessation of smoking advice, dietary advice, adjustment of medications to optimize medical conditions such as preexisting renal disease, and cessation of potentially teratogenic agents such as warfarin and angiotensin-converting enzyme (ACE) inhibitors. Baseline levels for blood pressure, platelet function, renal function (plasma creatinine and urinary protein/creatinine ratios), and liver function should be recorded¹⁰.

CONCLUSION:

It is concluded that those who have been diagnosed with severe preeclampsia are more likely to experience recurrence in their next pregnancy; however, the phenotype is typically less severe, with presentation approximately 2–3 weeks later in gestation. Women who have experienced severe early onset preeclampsia, especially if complicated by growth restriction or late fetal loss, should undergo testing for antiphospholipid syndrome. It may be necessary to discuss the implications of these results on future pregnancies.

REFERENCES:

1. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The calcium for preeclampsia prevention (CPEP) study group. *Am J Obstet Gynecol.* 1997;177:1003–10.
2. Gopalan C, Sastri RB, Balasubramanian SC, Rao BS, Deosthale YG, Pant KC. Hyderabad: National Institute of Nutrition, ICMR; 2011. Nutritive Value of Indian Foods.
3. Kumar N, Shekhar C, Kumar P, Kundu AS. Kuppuswamy's socioeconomic status scale-updating for 2007. *Indian J Pediatr.* 2007;74:1131–2.
4. Pijnenborg R, Vercruyssen L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. *Placenta.* 2006;27(9–10):939–958.
5. Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed

- hypertension. Calcium for Preeclampsia Prevention Study Group. *Obstet Gynecol.* 2000;95(1):24–28.
6. Sibai BM, Spinnato JA, Watson DL, Hill GA, Anderson GD. Pregnancy outcome in 303 cases with severe preeclampsia. *Obstet Gynecol.* 1984;64(3):319–325.
 7. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ.* 2007;335(7627):974.
 8. Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. *BMJ.* 2005;330(7491):576–580.
 9. Coonrod DV, Hickok DE, Zhu K, Easterling TR, Daling JR. Risk factors for preeclampsia in twin pregnancies: A population-based cohort study. *Am J Obstet Gynecol.* 1995;85:645–50.
 10. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: Current concepts. *Am J Obstet Gynecol.* 1998;179:1359–75.